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a b s t r a c t
Aims: The inﬂuence of discordance in what is important in being cured from depression on clinical
outcome at 6 months, assessed with a divergence index.
Methods: 304 outpatients treated for depression by general practitioners or by psychiatrists and
completing a 6-month treatment period: a divergence index (divergence between physician and patient
view on what is important in being cured from depression) was calculated for each physician–patient
pair. The relation between this index and outcome at 6 months was analyzed (including depressive,
anxious and somatic symptom severity, positive effect, functional impairment and quality of life
(psychological and social relations).
Results: Response rates (50% improvement) were 65.9% for depressive symptomatology and 46.2% for
anxious symptomatology. The subgroup with a poor physician–patient agreement (highest quartile) on
expectations had a worse clinical outcome than the subgroup with an excellent physician–patient
agreement (lowest quartile): differences in response rate between these groups ranged from 9% to 27%;
this difference reached statistical signiﬁcance for 3 outcome variables (anxiety, positive effect and social
relationships).
Conclusions: The study shows that outcomes with standard antidepressant drugs are still suboptimal and
that discordance between what patients' and physicians' consider important in the deﬁnition of cure
from depression signiﬁcantly inﬂuences clinical outcomes at 6 months.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
A meta-regression analysis showed that response rates are 53.8%
for a typical antidepressant and 37.3% for placebo suggesting that
about two thirds of antidepressant efﬁcacy is due to a non-speciﬁc
placebo effect (Papakostas and Fava, 2009). But again, important
differences were found between observer-rated and self-rated out-
comes. Using non-disease speciﬁc scales, it has indeed been reported
that the percentage of patients with a ‘global improvement’ during
antidepressant treatment was 10% higher in the physician's assess-
ment than in the patient's assessment (Demyttenaere et al., 2009a,
2009b). Moreover, in a group of patients being in (observer-rated)
remission (i.e. a HDRS – Hamilton Depression Rating Scale – r7),
only 55111% considered themselves in remission (not deﬁned, but
based on personal conceptualization of remission) (Hamilton, 1960;
Zimmerman et al., 2012). Interestingly, patients in observer-rated
remission who also considered themselves in remission had higher
scores on positive mental health and had signiﬁcantly less functional
impairment than patients with only observer-rated remission
(Zimmerman et al., 2012).
The reasons for these clinically important discrepancies have
been insufﬁciently investigated and they could theoretically be
inﬂuenced by clinical variables, trial or design features, patient
attitudes and behaviors, and doctor–patient relationship. For exam-
ple, it has been shown that a higher baseline discrepancy between
scores derived from an observer-scale and a self-rating scale leads
to a poorer outcome, is generally observed in patients with a
comorbid personality disorder and positively correlates with anxi-
ety levels (Rane et al., 2010). Factors related to patient expecta-
tions from antidepressant have also been shown to inﬂuence
outcome. Response rates in patients treated with an antidepressant
were found to be 65.4% in drug–drug studies, 57.7% in
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drug–drug–placebo studies and 51.7% in drug–placebo studies
while in patients treated with placebo, response rates were 44.6%
in drug–drug–placebo trials and 34.3% in drug–placebo trials
(Sinyor et al., 2010). This is further illustrated by a study showing
higher HDRS scores immediately postrandomization (moving to
placebo or staying on ﬂuoxetine): this increase in HDRS scores was
found as well in patients staying on ﬂuoxetine as in patients moving
to placebo (Rutherford et al., 2014). This suggests that treatment
changes inﬂuence paitents' expectations of improvement, which, in
turn, affect their depression symptom severity. These data suggest
that the chance of being on active treatment (through physician and
patient expectations) is an important predictor of outcome. Another
study investigating the inﬂuence of baseline attitude to taking
(antidepressant) medication showed that patients with a baseline
positive/neutral/negative attitude towards antidepressants pre-
sented a placebo response rate of 46%, 37% and 30% and an
antidepressant response rate of 67%, 60% and 56%, respectively,
again suggesting that baseline expectations and attitudes predict
outcome (Demyttenaere et al., 2011). The NIMH-funded study on
the efﬁcacy of hypericum perforatum did not ﬁnd any signiﬁcant
difference in response rates between the hypericum arm, the
sertraline arm and the placebo arm but a reanalysis taking into
account patient's guess of which treatment they got showed
important differences in outcome: patients guessing they were on
sertraline had a 56% response rate, patients guessing they were on
hypericum had a 68% response rate while patients guessing they
were on placebo had a 24% response rate (Hypericum Depression
Trial Study Group, 2002; Chen et al., 2011). Further, the attitude and
behavior of the prescribing psychiatrists are also important: the
psychiatrist is not only a provider of treatment but also acts as a
mean of treatment. Indeed, the proportion of variability in out-
comes was shown to be due less to the antidepressant treatment
received (imipramine or placebo) than to the psychiatrist adminis-
tering the treatment (McKay et al., 2006). Interestingly, the psy-
chiatrist effects were not as dramatic for the observer-rated
measure than for the self-report measure (6.7% and 9.1% of the
variance, respectively).
We previously showed that what physicians and patients
consider to be important in being cured from depression is
different, and the present paper investigates whether these
differences inﬂuence outcome in depressed patients treated with
antidepressants.
2. Methods
Ethics statement, patient recruitment and data collection were
described in the previous paper (Demyttenaere et al., submitted).
2.1. Treatment and clinical outcome
The protocol stipulated that the treatment was entirely left to
the discretion of the physician: one antidepressant was prescribed
to 92.5% of the patients and two antidepressants were prescribed
to 7.1% of the patients (no antidepressant was prescribed to 0.2% of
the patients and 43 different antidepressants were prescribed to
0.2% of the patients). In 45.2% of the patients, at least one
modiﬁcation in the antidepressant treatment was observed during
the 6-month study period.
The clinical status of the patient was assessed with the following
mentioned self-rating scales: the Patient Health Questionnaire-
Depression (PHQ-depression; depressive symptoms), Hospital Anxi-
ety and Depression Scale-anxiety (HADS-anxiety; anxious symp-
toms), Patient Health Questionnaire-Somatic Symptoms severity
(PHQ-somatic; somatic symptoms), the Positive And Negative
Affect Schedule-Positive effect subscale (PANAS-positive effect), the
Sheehan Disability Scale (SDS; functional impairment), and the
Abbreviated World Health Organization QoL (WHOQOL-BREF; qual-
ity of life-psychological and social relationships), at baseline and after
6 months of treatment (Kroenke et al., 2001, 2002; Zigmond and
Snaith, 1983; Watson et al., 1988; Sheehan et al., 1996; WHO-QOL
group, 1998).
2.2. Statistical analysis
Discordance index based on the top 10 DEsCRIBE™ items of the
patient.
The discordance between what patients and physicians con-
sider important in deﬁning cure from depression was based on
their respective baseline scores on the DEsCRIBE™questionnaire,
where a ranking (importance for being cured from disorder) was
given to depressive, anxious and somatic symptoms, positive
effect, disability and quality of life items (Demyttenaere et al.,
submitted). A discordance index (DI) was constructed to evaluate
the baseline agreement between physician and patient on the
deﬁnition of being cured from depression. The discordance index
was calculated for each possible pair (physician–patient) by using
the differences between the item scores given by the physician
and his/her patient. The items considered in the construction of
the discordance index were the 10 DEsCRIBE™ items classiﬁed in
ﬁrst position of importance by the patients in the deﬁnition of
being cure from depression. To correct for the fact that patients
always gave higher scores than physicians, individual patient's
scores were standardized by subtracting the corresponding mean
of each item. The same correction was applied to the individual
physician's scores. The absolute difference between the standar-
dized score of the patient and the standardized score of the
physician was calculated for each of the 10 selected items. The
discordance index was then deﬁned as the average of the 10
absolute differences. DI scores range between 0 and 5, where high
values indicate strong divergence and low values strong agree-
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The mean DI was 1.170.57 and the median 0.99. Based on their
DI value, patients were classiﬁed into 4 groups (according to the
quartiles): excellent agreement with physician (DIo0.71), rather
good agreement (0.71r DI o0.99), rather poor agreement
(0.99r DI o1.47), and poor agreement (DI Z1.47).
Results were summarized as mean and standard deviation (SD)
for quantitative variables and scores; counts and proportions (%)
were used for categorical variables. The correlation coefﬁcient was
computed to measure the association between two quantitative
variables. Mean values were compared by one-way analysis of
variance (ANOVA). Proportions were compared by the chi-squared
test for contingency tables. The comparison of the clinical score at
6 months according to DI-categories was made by ordinal logistic
regression. A Cochran–Armitage test for trend was used to com-
pare the 6-month response rates between the DI groups. Results
were considered signiﬁcant at the 5% critical level (Po0.05).
Calculations were always done on the maximum number of data
available. All statistical calculations were performed by using SAS
(version 9.3 for Windows) and S-PLUS (version 8.1) packages.
3. Results
Of the 426 patients analyzed in the study, 304 (71.3%)
completed the 6-month follow-up. Clinical status (responses and
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50%-improvement rates) for the different clinical scales used to
assess the outcome are given in Table 1. The PHQ-depression scores
at 6 months showed that 11% of the patients were still suffering
from major depression, 65.9% were responders (50% improvement)
and only 49% were in remission (PHQ depression r4). The HADS-
anxiety scores at 6 months showed that 24.4% of the patients were
still probable cases for an anxiety disorder and that 46.2% were
responders (50% improvement). Treatment changes between base-
line and 6 months follow-up were found in 45.2% of the patients,
and increasing the dose was the most frequently found strategy
(21.5%) followed by switching (9.2%). The largest improvement, i.e.
response rates, was found for depressive symptoms, functional
impairment and psychological aspects of quality of life (65.9%,
54.9% and 52.7%, respectively) and the smallest improvement was
found for social relationships in quality of life, somatic symptoms
and anxiety symptoms (35.7%, 46.2% and 46.2%, respectively).
The discordance index based on the top 10 DEsCRIBE™ items of the
patient, reﬂecting how far the physician reported important items in
deﬁning cure from depression were from the patient reported ones,
was negatively correlated with the age of the patient ( r¼0.10;
P¼0.03). The discordance index was also signiﬁcantly higher in drop-
outs than in completers (1.2070.55 versus 1.1070.58; P¼0.03),
especially in the subgroup of drop-outs due to patient's refusal to
continue the medication (1.3870.54). Finally, the discordance index
was signiﬁcantly correlated with the length of the current depressive
episode (weeks) (r¼0.13; P¼0.006) but not with the number of
previous episodes.
The relation between the baseline discordance index and
clinical outcome was tested in two ways: excellent, rather good/
good, rather poor/weak and poor/poor baseline agreement versus
6-month mean score and versus 6-month response rates (50%
improvement, i.e. a decrease of minimum 50% from baseline for
the scales assessing depression, anxiety, somatic symptoms, func-
tional impairment) or an increase of minimum 50% from baseline
for the scores on positive effect-quality of life) for the different
scales. When looking at the mean scores at 6 months, a greater
discordance between physician and patient resulted in a numeri-
cally worse score on all scales but this reached statistical sig-
niﬁcance only for somatic symptoms (and with a trend for
depressive symptomatology, anxious symptomatology and posi-
tive effect) (Table 2 and Fig. 1a). Response rates on the depression
questionnaire for excellent, rather good, rather poor and poor
agreement were 72%, 62%, 66% and 63%, respectively (P¼0.68) and
remission rates on the same questionnaire (PHQ-depressive r4)
were 56%, 48%, 44% and 46%, respectively (P¼0.49). When looking
at response rates at 6 months, a poorer agreement resulted in a
numerically lower response rate on all scales but this reached
statistical signiﬁcance only for anxiety symptoms, positive effect
and social relationships in quality of life (Table 3 and Fig. 1b).
4. Discussion
The current study again underscores the suboptimal treatment
in patients with a major depressive episode. After 6 months,
response (50% improvement) in depressive symptomatology is
achieved in only 65.9% of the patients, and remission only in 49%
of the patients. The outcome is even worse when looking at the
accompanying anxiety symptoms where response is achieved in
only 46.2% of the patients. These ﬁgures are in the same range as
those found in other large studies. The FINDER study showed a 6-
month remission rate of 50% for depression and also a lower
remission rate (40%) for anxiety disorders; STARnD found a 14-
week and a 1-year (with up to 4 treatment steps) remission rate of
37% and in 67% of patients, respectively (Demyttenaere et al.,
2009a, 2009b; Rush et al., 2006). It is worrying that after 6 months
of treatment, 11% of the patients still fulﬁll criteria for major
depression and 24% are yet probable cases for an anxiety disorder.
In the FINDER study, these ﬁgures were 25% and 33%, respectively
(Demyttenaere et al., 2009a,2009b). Since remission is the goal of
antidepressant treatment, compliance with guidelines (on the
physician side) is quite poor; although remission (for depression)
was reached in only 49%, changes in the treatment regimen were
noticed in merely 45% of patients. However, these ﬁgures are
higher than what was found in a very large naturalistic database
where therapy change rates during treatment with third-, second-
and ﬁrst-generation antidepressants was 19%, 21% and 43%,
respectively (Sheehan et al., 2008).
A discordance index was calculated to assess how much the
physician reported important items in deﬁning cure from depres-
sion were from the patient reported ones at baseline. A lower
discordance was found in older patients and a higher one in
patients with a longer duration of the current episode. The base-
line discordance was also higher in drop-outs than in completers
and especially in the subgroup of drop-outs due to the patient's
refusal to continue the medication, possibly suggesting that a high
concordance of expectations is related to a better adherence to
treatment.
The relation between the baseline discordance and clinical
improvement during 6 months of treatment was also investigated.
Interestingly there was a consistent trend for all outcome variables
(at 6 months) that a weak discordance between physicians and
patients resulted in a better outcome, although often only
numerically. For example, the difference in response rates between
the highest and lowest quartiles of the index (i.e. excellent versus
poor agreement) amounted 9% for depression, 22% for anxiety, 6%
for somatic symptoms, 27% for positive affect, 15% for functional
impairment, 13% for the psychological aspects of quality of life, and
15% for the social relationships aspects of quality of life; these
differences reach statistical signiﬁcance for anxiety, positive affect
and the social relationships aspects of quality of life. To put these
ﬁgures into perspective, it is important to notice that in rando-
mized clinical trials, the difference in response rates between
antidepressants and placebo is 15.5%. Further, the difference in
response rates between patients with a positive attitude towards
taking an antidepressant and patients with a negative attitude
towards taking an antidepressant reached 16% in patients on
placebo and 11% in patients on an antidepressant (Demyttenaere
et al., 2011). Anyhow, these differences taking into account
expectations and attitudes are much larger than differences
between different classes of antidepressant drugs: e.g. it was
shown that the difference in response rates between venlafaxine
and SSRIs was 4.3% in 8-week randomized clinical trials and that
the difference in remission rates in a 6-month open-label trial
between venlafaxine and SSRIs was only 3.5% (Papakostas et al.,
2007; Thase et al., 2011).
To the best of our knowledge, this is the ﬁrst paper investigat-
ing whether the discordance between what physician or patients
Table 1
Clinical status at baseline and at 6 months.
Scale Baseline 6 months 6-month response
rate (%)
PHQ9-depression 16.575.8 6.4075.6 65.9
HADS-anxiety 12.973.9 7.1174.5 46.2
PHQ-somatic 9.6974.8 5.8674.4 37.6
PANAS-positive 21.177.1 31.479.3 47.1
SDS-total 19.276.8 10.079.0 52.8
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report as important items in deﬁning cure from depression
inﬂuences outcome in depression. We can only speculate why this
discordance signiﬁcantly inﬂuences outcome (anxiety, positive
affect, and social relationships in quality of life). The literature
reports several studies investigating either patient or physician
expectations or therapeutic alliance but not the combination of these
factors. For example, a study used path analysis to show that patients'
treatment expectancies signiﬁcantly inﬂuenced clinical improvement
but only indirectly through the patient alliance; and that therapists'
global expectancies also inﬂuence clinical improvement partly directly
and partly through the patient alliance (valid conclusions for the
4 different treatment arms: cognitive-behavior therapy, interpersonal
therapy, imipramineþclinical management, placeboþclinical man-
agement) (Meyer et al., 2002). Another interesting paper suggested
that a good communication and a good alliance are even more
important for some subgroups of patients; it was for example shown
that a good communication and a good alliance were important for
outcome (in diabetic control) mainly in patients with a dismissing
attachment style (Ciechanowski et al., 2001).
Our research protocol did not include a scale assessing doctor–
patient alliance but it could well be hypothesized that more
common expectations are related to a better alliance. Anyhow, a
lower discordance index illustrating more common expectations
from antidepressant treatment and so probably a better therapeu-
tic alliance between a patient and a physician could augment the
efﬁcacy of the prescribed drug, have a direct effect on clinical
Table 2
Baseline discordance index and clinical status at 6 months (scores on different psychometric tests).
Scale Baseline agreement between physician and patient P-valuen
Excellent Rather good Rather poor Poor
PHQ9-depression 5.775.3 6.275.3 6.875.9 7.176.1 0.09
HADS-anxiety 6.074.1 7.774.0 7.274.9 7.674.9 0.07
PHQ-somatic 5.273.9 5.773.9 6.175.3 6.874.5 0.04
PANAS-positive 32.879.5 31.078.7 31.779.4 29.779.5 0.09
SDS-total 8.978.9 10.178.5 9.478.8 11.8710.0 0.11
WHOQOL-BREF psychological 59.5721.1 57.8719.4 59.3721.3 56.9721.2 0.58
WHOQOL-BREF social relations 62.3721.4 58.4721.3 60.5723.9 57.6722.3 0.31












































































































Excellent Rather good Rather poor Poor
Fig. 1. Baseline agreement between physician and patient and clinical outcome: (a) clinical status at 6 months, (b) evolution from baseline to 6 months.
Table 3
Baseline discordance index and clinical status at 6 months (response rates – 50%
improvement—for different psychometric tests).












PHQ9-depression 72 62 66 63 0.68
HADS-anxiety 62 41 44 40 0.02
PHQ-somatic 42 34 38 36 0.61
PANAS-positive 66 38 47 39 0.01
SDS-total 63 52 56 48 0.38
WHOQOL-BREF
psychological
65 48 46 52 0.13
WHOQOL-BREF social
relations
51 32 22 36 0.02
n Trend test.
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Fig. 1. (continued)
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outcome or on outcome in the presence of the prescribed drug
(Zuroff and Blatt, 2006). It cannot be forgotten that about two
thirds of the antidepressant effect is ‘placebo’ but the latter refers
to the common features of care: therapeutic alliance, hope,
expectation, remoralization, receipt of an explanatory system, con-
vincing rationale, therapeutic relationship, rituals, healing context
including the patient's and the physician's beliefs and represen-
tations.
In conclusion, the present study illustrates that outcomes with
standard antidepressant drugs are still suboptimal and that base-
line discordance between physician and patient reported impor-
tant items in deﬁning cure from depression signiﬁcantly inﬂuence
clinical outcomes at 6 months, mainly for anxiety, positive affect
and social relationships in quality of life.
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